Table 1.
Clinicopathologic characteristics of the stage I/II ovarian cancer patients.
| Characteristic | N (%) | ||
|---|---|---|---|
| All stages, N = 35 | Stage I, N = 28 (80%) | Stage II, N = 7 (20%) | |
| Age at diagnosis | |||
| Median/mean | 59/57.63 | 59/56.86 | 59/60.71 |
| Range | (34–83) | (34–78) | (51–83) |
| Grade | |||
| 0 | 2 (5.7) | 2 (7.1) | |
| 1 | 12 (34.3) | 10 (35.7) | 2 (28.6) |
| 2 | 8 (22.9) | 5 (17.9) | 3 (42.9) |
| 3 | 13 (37.1) | 11 (39.3) | 2 (28.6) |
| Histological subtype | |||
| Serous | 11 (31.4) | 9 (32.1) | 2 (28.5) |
| Endometrioid | 20 (57.2) | 16 (57.2) | 4 (57.2) |
| Clear-cell | 4 (11.4) | 3 (10.7) | 1 (14.3) |
| Debulking status | |||
| Optimal | 34 (97.1) | 28 (100) | 6 (85.7) |
| Suboptimal | 1 (2.9) | 1 (14.3) | |
| Response to therapy | |||
| CRa | 33 (94.3) | 27 (96.4) | 6 (85.7) |
| PDb | 2 (5.7) | 1 (3.6) | 1 (14.3) |
| Survival | |||
| Ovarian cancer deaths | 6 (17.1) | 4 (14.3) | 2 (28.5) |
| Total number of deaths | 6 (17.1) | 4 (14.3) | 2 (28.5) |
aComplete response.
bProgressive disease.